Idebenone significantly attenuated the fall in PEF % p from baseline to week 52 in the mITT ( -305 % p [ 95 % CI -708 to 097 ] , p = 0134 , vs placebo -901 % p [ -1318 to -484 ] , p = 00001 ; difference 596 % p [ 016 to 1176 ] , p = 0044 ) and ITT populations ( -257 % p [ -668 to 154 ] , p = 0215 , vs -884 % p [ -1273 to -495 ] , p < 00001 ; difference 627 % p [ 061 to 1193 ] , p = 0031 ) .